On December 30, 2022, IPSEN published the results of their Phase III Clinical Trial of the drug palovarotene in the Journal of Bone and Mineral Research.

To support understanding of these results by FOP families, a graphical plain language summary of the results was published in Future Medicine on January 18, 2023.

The IFOPA is grateful to the 99 individuals with FOP who enrolled in the MOVE Phase III Trial. The willingness of families to participate in clinical trial research is the only way we will ever learn if drugs are safe and effective treatments for FOP. We also appreciate the work of the trial investigators and their commitment to FOP families. We are also grateful to IPSEN for their commitment to the FOP community and the development of palovarotene.  

Questions about this publication? Contact us at [email protected]